340 related articles for article (PubMed ID: 7318921)
1. Lithium dissociates haloperidol-induced behavioral supersensitivity from reduced dopac increase in rat striatum.
Meller E; Friedman E
Eur J Pharmacol; 1981 Nov; 76(1):25-9. PubMed ID: 7318921
[TBL] [Abstract][Full Text] [Related]
2. Developmental change in striatal concentration of homovanillic acid and 3,4-dihydroxyphenylacetic acid in response to apomorphine and haloperidol treatment.
Nomura Y; Komori T; Okuda S; Segawa T
Arch Int Pharmacodyn Ther; 1979 Jan; 237(1):25-30. PubMed ID: 485682
[TBL] [Abstract][Full Text] [Related]
3. Influence of lithium on biochemical manifestations of striatal dopamine target cell supersensitivity induced by prolonged haloperidol treatment.
Le Douarin C; Oblin A; Fage D; Scatton B
Eur J Pharmacol; 1983 Sep; 93(1-2):55-62. PubMed ID: 6628547
[TBL] [Abstract][Full Text] [Related]
4. Effects of chronic lithium treatment on dopamine receptors in the rat corpus striatum. II. No effect on denervation or neuroleptic-induced supersensitivity.
Staunton DA; Magistretti PJ; Shoemaker WJ; Deyo SN; Bloom FE
Brain Res; 1982 Jan; 232(2):401-12. PubMed ID: 6322915
[TBL] [Abstract][Full Text] [Related]
5. The effects of chronic lithium on behavioral and biochemical indices of dopamine receptor supersensitivity in the rat.
Pittman KJ; Jakubovic A; Fibiger HC
Psychopharmacology (Berl); 1984; 82(4):371-7. PubMed ID: 6427831
[TBL] [Abstract][Full Text] [Related]
6. Modulating role of lithium on dopamine turnover, prolactin release, and behavioral supersensitivity following haloperidol and reserpine.
McIntyre IM; Kuhn C; Demitriou S; Fucek FR; Stanley M
Psychopharmacology (Berl); 1983; 81(2):150-4. PubMed ID: 6415746
[TBL] [Abstract][Full Text] [Related]
7. Effects of cyclo (Leu-Gly) on neurochemical indices of striatal dopaminergic supersensitivity induced by prolonged haloperidol treatment.
Le Douarin C; Fage D; Scatton B
Life Sci; 1984 Jan; 34(4):393-9. PubMed ID: 6694528
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity.
Pert A; Rosenblatt JE; Sivit C; Pert CB; Bunney WE
Science; 1978 Jul; 201(4351):171-3. PubMed ID: 566468
[TBL] [Abstract][Full Text] [Related]
9. Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity.
de Graaf CJ; Korf J
Psychopharmacology (Berl); 1986; 90(1):54-7. PubMed ID: 3094062
[TBL] [Abstract][Full Text] [Related]
10. Apomorphine- and haloperidol-induced change in 3,4-dihydroxyphenylacetic acid content in the mesolimbic-striatum of the developing rat.
Nomura Y; Oki K; Segawa T
J Pharmacobiodyn; 1980 Feb; 3(2):111-6. PubMed ID: 7205536
[TBL] [Abstract][Full Text] [Related]
11. Effects of apomorphine on morphine analgesia during the state of dopaminergic supersensitivity after chronic treatment with haloperidol.
Kamata K; Ogawa K; Noma S; Kameyama T
J Pharmacobiodyn; 1986 Jan; 9(1):88-94. PubMed ID: 3712211
[TBL] [Abstract][Full Text] [Related]
12. The behavioral and biochemical effects of lithium on dopaminergic agonist-induced supersensitivity.
Rubin EH; Wooten GF
Psychopharmacology (Berl); 1984; 84(2):217-20. PubMed ID: 6438680
[TBL] [Abstract][Full Text] [Related]
13. Lithium does not interact with haloperidol in the dopaminergic pathways of the rat brain.
Reches A; Jackson-Lewis V; Fahn S
Psychopharmacology (Berl); 1984; 82(4):330-4. PubMed ID: 6427824
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of haloperidol-induced increase in rat striatal or mesolimbic 3,4-dihydroxyphenylacetic acid and homovanillic acid by pretreatment with chronic methamphetamine.
Toru M; Mataga N; Takashima M; Nishikawa T
Psychopharmacology (Berl); 1981; 74(4):316-20. PubMed ID: 6794073
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the synthesis and metabolism of striatal dopamine after disruption of nerve conduction in the medial forebrain bundle.
Commissiong JW; Slimovitch C; Toffano G
Br J Pharmacol; 1990 Apr; 99(4):741-9. PubMed ID: 2361171
[TBL] [Abstract][Full Text] [Related]
16. Tolerance to fluphenazine and supersensitivity to apomorphine in central dopaminergic systems after chronic fluphenazine decanoate treatment.
Wheeler SC; Roth RH
Naunyn Schmiedebergs Arch Pharmacol; 1980 Jun; 312(2):151-9. PubMed ID: 7190650
[TBL] [Abstract][Full Text] [Related]
17. Behavioral and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: studies with chronic clozapine and haloperidol.
Seeger TF; Thal L; Gardner EL
Psychopharmacology (Berl); 1982; 76(2):182-7. PubMed ID: 6805029
[TBL] [Abstract][Full Text] [Related]
18. Chronic molindone treatment: relative inability to elicit dopamine receptor supersensitivity in rats.
Meller E
Psychopharmacology (Berl); 1982; 76(3):222-7. PubMed ID: 6808540
[TBL] [Abstract][Full Text] [Related]
19. Decrease in the evoked release of endogenous dopamine and dihydroxyphenylacetic acid from rat striatal slices after withdrawal from repeated haloperidol.
Umeda Y; Sumi T
Eur J Pharmacol; 1990 Nov; 191(2):149-55. PubMed ID: 2086236
[TBL] [Abstract][Full Text] [Related]
20. Effects of intranigral administration of dopamine agonists and antagonists and baclofen on concentrations of dopac and dopamine in the striatum and substantia nigra of the rat.
Wuerthele SM; Friedle NM; Moore KE
J Neural Transm; 1979; 45(2):117-27. PubMed ID: 469523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
